CONTACT US
Home > APIs> > Diflunisal
22494-42-4-Diflunisal Diflunisal

Diflunisal

For research use only. Not for therapeutic Use.

  • CAT Number: A000051
  • CAS Number: 22494-42-4
  • Molecular Formula: C13H8F2O3
  • Molecular Weight: 250.201
  • Purity: ≥95%
Inquiry Now
Related products: Levomedetomidine (hydrochloride)     Aluminum Zirconium Tetrachlorohydrex Gly     Sodium Nitrite    
Research Areas: Inflammation&Immunology Research     NF-κB&JAK/STAT Signaling Pathways    

Diflunisal is a salicylic acid derivative with analgesic and anti-inflammatory activity. It was developed by Merck Sharp & Dohme in 1971 after showing promise in a research project studying more potent chemical analogs of aspirin. It was first sold under the brand name Dolobid, marketed by Merck & Co., but generic versions are now widely available. It is classed as a non-steroidal anti-inflammatory drug (NSAID).


Catalog Number A000051
CAS Number 22494-42-4
Synonyms

Dolobid, Dolobis, Flovacil, Fluniget

Molecular Formula C13H8F2O3
Purity ≥95%
Target COX
Solubility Soluble in DMSO
Storage Store at -20°C
IUPAC Name 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
InChI InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
InChIKey HUPFGZXOMWLGNK-UHFFFAOYSA-N
SMILES C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O
Reference

1: Kaur A, Bhoop BS, Chhibber S, Sharma G, Gondil VS, Katare OP. Supramolecular
nano-engineered lipidic carriers based on diflunisal-phospholipid complex for
transdermal delivery: QbD based optimization, characterization and preclinical
investigations for management of rheumatoid arthritis. Int J Pharm. 2017 Nov
25;533(1):206-224. doi: 10.1016/j.ijpharm.2017.09.041. Epub 2017 Sep 21. PubMed
PMID: 28943207.

<br>
2: Duret G, Pereira FA, Raphael RM. Diflunisal inhibits prestin by
chloride-dependent mechanism. PLoS One. 2017 Aug 17;12(8):e0183046. doi:
10.1371/journal.pone.0183046. eCollection 2017. PubMed PMID: 28817613; PubMed
Central PMCID: PMC5560734.
<br>

3: Pandey P, Verma V, Gautam G, Kumari N, Dhar SK, Gourinath S. Targeting the
β-clamp in Helicobacter pylori with FDA-approved drugs reveals micromolar
inhibition by diflunisal. FEBS Lett. 2017 Aug;591(15):2311-2322. doi:
10.1002/1873-3468.12734. Epub 2017 Jul 26. PubMed PMID: 28656718.
<br>

4: Pallipurath AR, Civati F, Sibik J, Crowley C, Zeitler JA, McArdle P, Erxleben
A. A comprehensive spectroscopic study of the polymorphs of diflunisal and their
phase transformations. Int J Pharm. 2017 Aug 7;528(1-2):312-321. doi:
10.1016/j.ijpharm.2017.06.020. Epub 2017 Jun 8. PubMed PMID: 28603011.
<br>

5: Azorín SE, Cabib CE, Campistol JM. Diflunisal compassive use in transthyretin
hereditary amyloid polyneuropathy: report of a first Spanish experience. Amyloid.
2017 Mar;24(sup1):105-106. doi: 10.1080/13506129.2017.1291424. PubMed PMID:
28434315.
<br>

6: Tarushi A, Kakoulidou C, Raptopoulou CP, Psycharis V, Kessissoglou DP, Zoi I,
Papadopoulos AN, Psomas G. Zinc complexes of diflunisal: Synthesis,
characterization, structure, antioxidant activity, and in vitro and in silico
study of the interaction with DNA and albumins. J Inorg Biochem. 2017
May;170:85-97. doi: 10.1016/j.jinorgbio.2017.02.010. Epub 2017 Feb 12. PubMed
PMID: 28231454.
<br>

7: Kaur A, Goindi S, Katare OP. Formulation, characterisation and in vivo
evaluation of lipid-based nanocarrier for topical delivery of diflunisal. J
Microencapsul. 2016 Aug;33(5):475-86. doi: 10.1080/02652048.2016.1216189. Epub
2016 Aug 8. PubMed PMID: 27499126.
<br>

8: Hendrix AS, Spoonmore TJ, Wilde AD, Putnam NE, Hammer ND, Snyder DJ, Guelcher
SA, Skaar EP, Cassat JE. Repurposing the Nonsteroidal Anti-inflammatory Drug
Diflunisal as an Osteoprotective, Antivirulence Therapy for Staphylococcus aureus
Osteomyelitis. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5322-30. doi:
10.1128/AAC.00834-16. Print 2016 Sep. PubMed PMID: 27324764; PubMed Central
PMCID: PMC4997817.
<br>

9: Perontsis S, Hatzidimitriou AG, Papadopoulos AN, Psomas G. Nickel-diflunisal
complexes: synthesis, characterization, in vitro antioxidant activity and
interaction with DNA and albumins. J Inorg Biochem. 2016 Sep;162:9-21. doi:
10.1016/j.jinorgbio.2016.06.003. Epub 2016 Jun 4. PubMed PMID: 27318424.
<br>

10: Shirakawa K, Wang L, Man N, Maksimoska J, Sorum AW, Lim HW, Lee IS, Shimazu
T, Newman JC, Schr&#246;der S, Ott M, Marmorstein R, Meier J, Nimer S, Verdin E.
Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit
anticancer activity. Elife. 2016 May 31;5. pii: e11156. doi: 10.7554/eLife.11156.
PubMed PMID: 27244239; PubMed Central PMCID: PMC4931907.

Request a Quote